To further understand the potential of BRD7929 as a therapeutic for the treatment for chronic toxoplasmosis, we tested whether treatment could prevent reactivation of latent infection using the Ifngr1−/− mouse model of chronic infection (Fig. 6d)27. This evidence concerns the gene IFNGR1 and disease arising from reactivation of latent virus.